Breast Journal最新文献

{"title":"Dosimetric Comparison of Five Radiotherapy Techniques in Left-Sided Breast Cancer Patients Following Breast-Conserving Surgery","authors":"Yanqiu Zhang,&nbsp;A’meng Han,&nbsp;Sen Yang,&nbsp;Jianxin Zhao,&nbsp;Xiumei Li","doi":"10.1155/tbj/6666976","DOIUrl":"10.1155/tbj/6666976","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aims to compare and evaluate the dosimetric characteristics of five radiotherapy techniques in left-sided breast cancer patients following breast-conserving surgery. The five radiotherapy techniques include three-dimensional conformal radiation therapy (3D-CRT), fixed-field intensity-modulated radiation therapy (ff-IMRT), volumetric modulated arc therapy (VMAT), hybrid 3D-CRT with IMRT (CRT + IMRT), and hybrid 3D-CRT with VMAT (CRT + VMAT).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients and Methods</h3>\u0000 \u0000 <p>Ten patients with left-sided breast cancer who received postlumpectomy radiotherapy at the Department of Radiation Oncology, First Hospital of Qinhuangdao, between June 1, 2020, and June 1, 2021, were randomly enrolled in this study. For each patient, five distinct treatment plans were designed using the five aforementioned techniques (3D-CRT, ff-IMRT, VMAT, CRT + IMRT, and CRT + VMAT) based on identical computed tomography (CT) imaging datasets. Dosimetric parameters for the tumor target volume, organs at risk (OARs), and normal tissues (defined as body minus planning target volume [PTV], termed B-P) were analyzed and compared using dose–volume histograms (DVHs) and isodose distributions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The CRT + VMAT technique demonstrated superior PTV dose coverage, conformity, and homogeneity compared to 3D-CRT, ff-IMRT, VMAT, and CRT + IMRT (<i>p</i> &lt; 0.05). In contrast, the VMAT technique achieved significantly lower V₃₀ (%) values for bilateral lungs and ipsilateral lung than 3D-CRT, ff-IMRT, CRT + IMRT, and CRT + VMAT (<i>p</i> &lt; 0.05). The CRT + IMRT technique reduced V₅ (%) values for bilateral lungs, ipsilateral lung, and heart compared to 3D-CRT, ff-IMRT, VMAT, and CRT + VMAT (<i>p</i> &lt; 0.05). Finally, 3D-CRT required the fewest monitor units (MUs) and shortest treatment time among all techniques (<i>p</i> &lt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Clinicians may tailor radiotherapy plans to individual patients based on the distinct dosimetric profiles of each technique. For patients requiring optimal PTV dose distribution, the CRT + VMAT technique is suggest. For enhanced cardiopulmonary protection (e.g., reduced lung/heart doses), ff-IMRT or CRT + IMRT may be prioritized. Additionally, 3D-CRT should be the first choice for patients needing rapid fractionated treatment due to its efficiency in minimizing MUs and treatment time.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13659263/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149168689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Clinicopathological Features and Postoperative Management on Prognosis in Male Breast Cancer","authors":"Shihe Liu,&nbsp;Qiying Song","doi":"10.1155/tbj/2806453","DOIUrl":"https://doi.org/10.1155/tbj/2806453","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Male breast cancer (MBC) represents a rare type of malignant tumor, comprising less than 1% of all breast cancer cases. Therapies for MBC patients are typically adapted from breast cancer treatments in women. This study systematically performed a retrospective evaluation of the clinicopathological features and prognostic determinants to offer evidence for a therapeutic strategy for MBC patients.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A total of 29 MBC patients were selected from PLA General Hospital in China from 2006 to 2023 and 2589 patients were retrieved from the Surveillance, Epidemiology, and End Results database with their registration periods spanning from 2016 to 2020. The clinicopathological features between different groups were compared using Pearson’s chi-square test (&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; test) or Fisher’ s exact test, as appropriate. Multivariate Cox proportional hazards regression analysis was utilized to assess the predictors of overall survival (OS). Subgroup analyses were further conducted to evaluate the therapeutic efficacy across different stages.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We identified 2618 patients totally. The primarily diagnosed median age of Chinese patients was younger than that of Western patients (59.8 years old vs 67.7 years old, &lt;i&gt;p&lt;/i&gt; = 0.001). The infiltrating duct carcinoma was the most common pathological type for both groups. The subtypes (&lt;i&gt;p&lt;/i&gt; = 0.622) and stages (&lt;i&gt;p&lt;/i&gt; = 0.385) at diagnosis were similar between the two groups. Surgery at the primary site could improve the OS of MBC patients including Stage IV (&lt;i&gt;p&lt;/i&gt; = 0.019). In stratified subgroup analyses, postoperative chemotherapy significantly improved OS in stages T2N1-3M0 and T3-4N1-3M0 MBC patients. Postoperative radiation was associated with favorable OS in early-stage (T1N0M0) and locally advanced (T3-4N1M0 and T1-4N2-3M0) MBC patients.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The median age at diagnosis for MBC patients in China was significantly younger compared to other populations. Postoperative chemotherapy significantly improved OS in patients with positive axillary lymph nodes and primary lesions exceeding 2 cm. Postoperative radiotherapy demonstrated survival benefits in partial early-stage and locally advanced patients. Additionally, surgery at the primary site represented a viable therapeutic option for selected Stage IV patients.&lt;/p&gt;\u0000 \u0000 &lt;p&gt;&lt;b&gt;Trial Registration:&lt;/b&gt; Chinese Clinical Trial: ChiCTR2500110646&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 ","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/2806453","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149146355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Modified Pectoral Nerve Block and Erector Spinae Plane Block for Postoperative Analgesia and Surgical Stress Response Following Modified Radical Mastectomy: A Prospective, Randomised, Blinded Study","authors":"Avnika Laller,&nbsp;Lalit Gupta,&nbsp;Devang Bharti,&nbsp;Kapil Chaudhary","doi":"10.1155/tbj/2712790","DOIUrl":"10.1155/tbj/2712790","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Erector spinae plane block (ESPB) and modified pectoral nerve block (PECS-II) are being increasingly used to control pain following breast surgeries. However, evidence comparing their effects on postoperative analgesia and surgical stress response is limited. The current study compared analgesic efficacy and surgical stress response attenuation of ESPB and PECS-II in patients undergoing modified radical mastectomy (MRM).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;In this prospective, randomised, comparative study, 42 patients undergoing elective MRM were randomly divided to receive either ESPB or PECS-II. Both groups received 30 mL of 0.2% ropivacaine with 0.5 μg/kg dexmedetomidine after induction of general anaesthesia (GA). The primary outcome was time to first rescue analgesia requirement. Secondary outcomes were postoperative numerical rating scale (NRS) scores, rescue analgesic consumption, intraoperative fentanyl requirement, serum cortisol, interleukin-6 (IL-6) and neutrophil-to-lymphocyte ratio (NLR), patient satisfaction and block-related complications.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The mean time to first rescue analgesia was significantly larger in the PECS-II group than in the ESPB group (9.05 ± 1.12 h vs 6.95 ± 1.16 h; &lt;i&gt;p&lt;/i&gt; &lt; 0.001). Patients receiving PECS-II had lower 24-h diclofenac (114.3 ± 38.4 mg vs 146.4 ± 16.4 mg; &lt;i&gt;p&lt;/i&gt; = 0.002) and tramadol consumption (7.1 ± 17.9 mg vs 23.8 ± 25.6 mg; &lt;i&gt;p&lt;/i&gt; = 0.021). NRS scores were lower in the PECS-II group at 6 h postoperatively (&lt;i&gt;p&lt;/i&gt; &lt; 0.001). Intraoperative fentanyl requirement was comparable between the two groups (&lt;i&gt;p&lt;/i&gt; = 0.133). Postoperative serum cortisol (363.48 ± 41.79 vs 495.95 ± 52.20 nmol/L), IL-6 (14.48 ± 4.39 vs 24.43 ± 6.33 pg/mL) and NLR (4.15 ± 0.55 vs 4.98 ± 0.85) were also lower in the PECS-II group (&lt;i&gt;p&lt;/i&gt; ≤ 0.001). Patient satisfaction scores were higher following PECS-II (5.62 ± 0.74 vs 5.05 ± 0.67; &lt;i&gt;p&lt;/i&gt; = 0.022). No block-related complications were observed in either group.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;PECS-II provided longer postoperative analgesia than ESPB in patients undergoing MRM under GA. Exploratory analyses showed lower postoperative analgesic consumption, lower pain scores at 6 h, lower postoperative stress response markers and higher patient satisfaction with PECS-II. These secondary findings should be considered hypothesis-generating and warrant confirmation in larger, adequately powered studies. Intraoperative fentanyl requirement was comparable between the two ","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13635797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149119064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lower-Cost Nonsurgical Primary Prevention Strategies for Women at High Risk of Breast Cancer: A Scoping Review","authors":"Menghua Wen,&nbsp;Youfu Zhao,&nbsp;Chunying He","doi":"10.1155/tbj/1523594","DOIUrl":"10.1155/tbj/1523594","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>A systematic mapping of nonsurgical, lower-cost primary prevention strategies for women at high risk of breast cancer remains limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To identify and summarize lower-cost (i.e., lower economic cost relative to surgical and pharmaceutical alternatives; not dependent on expensive equipment, patented drugs, or complex medical procedures; implementable through community, family, or self-management models), nonsurgical primary prevention strategies for women at high risk of breast cancer, providing empirical evidence to inform clinical practice, health education, and public health policy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Following the Joanna Briggs Institute (JBI) methodology for scoping reviews and the Participants, Concept, and Context (PCC) framework, we systematically searched 9 Chinese and English databases. Search terms covered “breast cancer,” “high-risk women,” “primary prevention,” and various nonsurgical strategies. Two independent reviewers performed literature screening and data extraction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seventeen studies were included, and six prevention strategy categories were identified: nutritional dietary interventions, physical activity interventions, comprehensive lifestyle interventions, chemoprevention, digital health interventions, and health education with self-management. Comprehensive lifestyle intervention emerged as the core strategy with robust evidence and manageable costs. Nutritional interventions have shifted from single nutrients to overall dietary patterns. Chemoprevention, limited by cost and side effects, is more suitable for very high-risk women. Digital health interventions and health education offer advantages in medically underserved areas.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This scoping review systematically maps lower-cost, nonsurgical primary prevention strategies for women at high risk of breast cancer, identifying six categories of promotable interventions. Comprehensive lifestyle intervention represents the most evidence-supported and economically manageable core strategy. For the first time from the dual perspectives of “nonsurgical” and “lower cost,” this review provides practical references for primary healthcare systems, clinical education, and public health policy, with particular relevance for resource-limited settings.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13628707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149119034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of CYP3A5 Genetic Variants With Elevated Breast Cancer Risk: A Case–Control and In Silico Analysis","authors":"Sm Faysal Bellah","doi":"10.1155/tbj/9977157","DOIUrl":"10.1155/tbj/9977157","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Cytochrome P450 3A5 (CYP3A5) is a key xenobiotic-metabolizing enzyme that also participates in the biotransformation of endogenous substrates. Functional genetic variation within CYP3A5 can alter enzyme activity and may consequently modify individual susceptibility to malignancy. The contribution of CYP3A5 genetic variation to breast cancer risk, as well as its potential relevance to tumor biology, remains inadequately characterized in the Bangladeshi population.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The current study investigated the relationship of CYP3A5∗3 (rs776746) polymorphism with the susceptibility of breast cancer and explored its relationship with immune infiltration and survival outcomes.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The study was conducted as a case–control study including 170 breast cancer patients and 170 age-matched healthy individuals. CYP3A5∗3 (rs776746) genotypes were determined using polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP) analysis. Genetic associations were calculated using odds ratios (ORs) with 95% confidence intervals (CIs). Complementary computational analyses evaluated the association of CYP3A5 expression with tumor immune-cell infiltration using TIMER2.0 and examined its prognostic relevance through survival data from TCGA accessed via UALCAN.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;CYP3A5∗3 genotype frequencies differed significantly between cases and controls. Compared with the wild-type genotype (∗1/∗1), the heterozygote (∗1/∗3) genotype (OR = 2.57; &lt;i&gt;p&lt;/i&gt; = 0.0016), mutant homozygote (∗3/∗3) (OR = 1.78; &lt;i&gt;p&lt;/i&gt; = 0.0376), and combined variant genotypes (∗1/∗3 + ∗3/∗3) (OR = 2.11; &lt;i&gt;p&lt;/i&gt; = 0.0010) were associated with increased breast cancer risk. The CYP3A5∗3 allele was more prevalent in cases than controls (36% vs. 25%; OR = 1.75; &lt;i&gt;p&lt;/i&gt; = 0.0009). In silico analysis showed that CYP3A5 expression was positively correlated with immune-cell infiltration of several immune cells. The elevated expression of CYP3A5 was linked to poorer survival in selected clinical subgroups.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The findings indicate that the CYP3A5∗3 polymorphism may contribute to genetic susceptibility to breast cancer among Bangladeshi women. Additionally, CYP3A5 expression shows a relationship with immune infiltration and may have subgroup-specific prognostic relevance in breast cancer.&lt;/p&gt;\u0000 ","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13624696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149082920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Neoadjuvant Chemotherapy Necessary for Male Breast Cancer? A SEER-Based Population Study","authors":"Liwei Pang,&nbsp;YiFan Li,&nbsp;Zhen Wang","doi":"10.1155/tbj/3718304","DOIUrl":"10.1155/tbj/3718304","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background and Aims&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Neoadjuvant chemotherapy (NAC) is widely utilized in female breast cancer to achieve disease downstaging, reduce distant dissemination, and assess chemosensitivity. However, the efficacy of NAC in male breast cancer (MBC) remains poorly understood. This study aimed to evaluate pathologic complete response (pCR) rates and overall survival (OS) outcomes following NAC in MBC patients, stratified by tumor subtype.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database for MBC patients who received NAC between 2000 and 2020. Patients were categorized by receptor status: hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−), HR+/HER2+, HR−/HER2+, and HR−/HER2−. The proportions of pCR (ypT0/Tis ypN0) were compared across subtypes. OS was estimated using the Kaplan–Meier method, and differences were analyzed using the log-rank test. Propensity score matching (PSM) was applied to reduce selection bias inherent to this retrospective observational study. Based on the baseline characteristics of breast cancer patients who received NAC, univariate Cox proportional hazards regression analysis was first performed to screen potential prognostic variables. Covariates with statistically significant differences in the univariate model were subsequently incorporated into the multivariate Cox regression model to identify independent risk factors associated with OS prognosis. Statistical analyses were performed using STATA 12.0 and SPSS Version 23.0.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A total of 260 MBC patients who received NAC were included in the analysis. No statistically significant difference in OS was observed between MBC and FBC patients receiving NAC (HR = 1.067; 95% CI: 0.929–1.226; &lt;i&gt;p&lt;/i&gt; = 0.358). However, female patients had a better OS (HR = 0.930; 95% CI: 0.913–0.948; &lt;i&gt;p&lt;/i&gt; &lt; 0.001) after PSM. Five-year OS for MBC patients with pCR versus non-pCR was 92% vs. 77.3% (HR = 1.236; 95% CI: 0.787–1.942; &lt;i&gt;p&lt;/i&gt; = 0.357). The results were further confirmed in the multivariate Cox regression model after PSM, in which pCR can be considered an independent prognostic factor. In addition, adjuvant chemotherapy demonstrated superior OS compared to NAC in MBC patients (HR = 3.223; 95% CI: 2.772–3.747; &lt;i&gt;p&lt;/i&gt; &lt; 0.001). The proportions of pCR by tumor subtype were as follows: (i) HR−/HER2+: 50.0% (&lt;i&gt;n&lt;/i&gt; = 3), (ii) HR−/HER2−: 41.7% (&lt;i&gt;n&lt;/i&gt; = 5), (iii) HR+/HER2+: 10.7% (&lt;i&gt;n&lt;/i&gt; = 7), and (iv) HR+/HER2−: 5.5% (&lt;i&gt;n&lt;/i&gt; = 9). OS was significantly worse with NAC compared to adjuvant chemotherapy in","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13579626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148978796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the Effect of Breast Density on Screening Performance in a Population-Based Program","authors":"Chirag Mistry,&nbsp;Richard Walton,&nbsp;Matthew Warner-Smith,&nbsp;Kan Ren,&nbsp;David Roder,&nbsp;Bronwyn Morley,&nbsp;Tracey O’Brien","doi":"10.1155/tbj/9750357","DOIUrl":"10.1155/tbj/9750357","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Breast density is both an independent risk factor for breast cancer and a major determinant of mammographic diagnostic performance. However, its impact on overall screening performance within population-based screening programs is less well understood.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective cohort study included women aged 50–74 years screened through BreastScreen NSW between 1 January 2016 and 31 December 2017, excluding first-time screeners above 70. Breast density was assessed using Lunit INSIGHT MMG (v1.1.7) generating an ordinal density score (1–10) and corresponding BI-RADS category (A–D). Screen-detected and interval cancers were ascertained via the NSW BreastScreen Information System and the NSW Cancer Registry. Standard screening performance metrics were calculated stratified by age, breast density and screening round.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The cohort comprised 564,681 screening episodes, with 4758 cancers diagnosed (3756 screen-detected; 1002 interval). Cancer incidence rates and screening performance varied by breast density. The proportion of cancers that were interval cancers increased markedly with increasing density, from 10.9% of cancers in category A (least dense) to 46.6% in category D. Recall rates followed an N-shaped pattern, peaking in density category C, while specificity mirrored this relationship.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The effectiveness of conventional two-dimensional mammography is strongly dependent on breast density, with reduced sensitivity and increased interval cancer rates for clients with extremely dense breasts. By utilising a more granular measure of breast density in a large population screening cohort, this study identified nonlinear relationships between breast density and screening performance metrics, providing evidence to support future evaluation of more individualised screening approaches.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540992/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study on the Pathway Mechanism of Social Support and Quality of Life Between Self-Disclosure and Stigma Among Breast Cancer Patients During Recovery","authors":"Siyin Lin,&nbsp;Beien Zhang,&nbsp;Shuxian Yu,&nbsp;Chao Wang,&nbsp;Jiaxing Zheng,&nbsp;Zhixin Cao,&nbsp;Hongtao Xu,&nbsp;Guanhua Fan","doi":"10.1155/tbj/8826025","DOIUrl":"10.1155/tbj/8826025","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Breast cancer comprehensive therapies often cause body image changes, triggering stigma that impairs mental health and quality of life. Existing studies lack an integrated model to reveal the underlying mechanisms between these variables.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A cross-sectional survey was conducted among 292 breast cancer patients selected via convenience sampling from 5 hospitals in Guangdong Province between March 2021 and March 2022. The Distress Disclosure Index (DDI), Consumer Experiences of Shame Questionnaire (CESQ), Functional Assessment of Cancer Therapy-Breast (FACT-B), and Multidimensional Scale of Perceived Social Support (PSSS) scales were administered. Pearson correlation analysis explored variable relationships, structural equation modeling (SEM) constructed the chain mediating model, the Bootstrap method tested mediating effects, and subgroup associations with stigma were analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Breast cancer patients had self-disclosure and stigma scores of 38.17 ± 0.54 and 13.74 ± 0.42, respectively. Stigma was significantly negatively correlated with self-disclosure, social support, and quality of life (all <i>p</i> &lt; 0.01). Self-disclosure was directly associated with lower stigma (<i>β</i> = −0.52, <i>p</i> &lt; 0.001) and indirectly mediated by two pathways: the independent pathway through “better quality of life” (11.6% of total effect) and the chain pathway through “higher social support and better quality of life” (5.4% of total effect). Subgroup analysis indicated that patients with a bachelor’s degree or above were more significantly associated with low stigma (OR = 0.42, 95% CI: 0.17–0.96), while introverted patients showed a stronger association with high stigma than extroverted ones (OR = 2.90, 95% CI: 1.57–5.56).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Breast cancer patients exhibit relatively low self-disclosure and moderate-to-low stigma. Higher self-disclosure is associated with lower stigma directly or indirectly via the chain mediation of social support and quality of life. Enhancing psychological counseling, social support, and quality of life, paired with targeted interventions for education and personality subgroups, facilitates physical and mental recovery and social reintegration.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13527388/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148868000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibition of miR-301a-3p Expression Promotes Ferroptosis: A New Target for Ferroptosis Treatment in TNBC","authors":"Baiyang Fu,&nbsp;Yuan Yao,&nbsp;Wenlong Liang,&nbsp;Yao Wang,&nbsp;Xi Chen,&nbsp;Jianguo Zhang","doi":"10.1155/tbj/9941495","DOIUrl":"10.1155/tbj/9941495","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The current treatment of triple-negative breast cancer (TNBC) remains challenging; however, regulating ferroptosis through miRNAs offers new insights for TNBC treatment strategies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Bioinformatics methods were used to screen ferroptosis-related differentially expressed genes (FRDEGs) in TNBC, and ferroptosis-related miRNAs were screened by combining gene-miRNA interaction network, miRNA survival analysis, and expression validation in clinical specimens. A nomogram was constructed to evaluate the prognostic impact of miR-301a-3p in TNBC. Cell proliferation and migration capabilities were assessed using the CCK-8 assay, colony formation assay, and wound healing assay, respectively. The intracellular protein expression of GPX4 was measured by Western blot, and fluorescent probes were used to detect intracellular ROS and Fe²⁺ levels.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>This study used bioinformatics methods to screen five FRDEGs in TNBC, thereby identifying six core miRNAs that can regulate these genes. Among these, miR-301a-3p expression was significantly upregulated in tumor tissues compared to adjacent normal tissues and was associated with poor patient prognosis. Subsequently, an excellent prediction model was established using miR-301a-3p expression information and patient clinicopathological information. Functional analyses revealed that miR-301a-3p promoted TNBC cell proliferation and migration. In addition, the inhibition of cell proliferation activity by miR-301a-3p inhibitor could be reversed by Ferrostatin-1, and miR-301a-3p inhibitor could inhibit the expression of GPX4 and promote the accumulation of intracellular ROS and Fe²⁺. The promotion of cell proliferation activity by miR-301a-3p mimic could be reversed by Erastin, and miR-301a-3p mimic could promote the expression of GPX4 and inhibit the accumulation of intracellular ROS and Fe²⁺.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In conclusion, this study provides evidence that inhibition of miR-301a-3p expression promotes ferroptosis in TNBC cells and produces a synergistic anti-cancer effect with Erastin, providing a new target for future TNBC ferroptosis treatment strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/9941495","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148842343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Algorithm for Salvage of Implant-Threatening Complications in Breast Reconstruction","authors":"Elizaveta Kouniavski,&nbsp;Shani Gilron,&nbsp;Moran Lemberger,&nbsp;Pnina Ciobotaro,&nbsp;Dana Egozi,&nbsp;Sharon L. Kracoff-Sella","doi":"10.1155/tbj/4668584","DOIUrl":"10.1155/tbj/4668584","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Implant-based breast reconstruction is associated with postoperative infectious and wound-related complications that may compromise reconstructive outcomes, particularly in cohorts predominantly undergoing immediate reconstruction. Optimal management remains controversial, with no universally accepted salvage algorithm.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective cohort study of 198 patients (285 breasts) who underwent implant-based reconstruction between 2013 and 2023, the majority of whom underwent immediate reconstruction. Implant-threatening complications were defined as surgical site infection according to Centers for Disease Control and Prevention (CDC) criteria, full-thickness skin necrosis, or deep wound dehiscence. A standardized institutional salvage protocol incorporating antibiotic therapy with or without surgical intervention was applied. Outcomes included implant salvage and final reconstruction status at the end of follow-up, and logistic regression was used to identify predictors of salvage failure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Implant-threatening complications occurred in 28.3% of patients, with salvage achieved in 51.8% of cases. All patients in the salvage group achieved final reconstruction, compared to 44.4% in the nonsalvage group (<i>p</i> &lt; 0.01). The most common complications were skin necrosis and wound dehiscence, followed by infection, and Gram-negative organisms predominated among culture-positive cases. Resistant organisms (<i>p</i> = 0.04), implant extrusion (<i>p</i> = 0.008), and prior radiation therapy (<i>p</i> = 0.019) were independent predictors of salvage failure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>A protocol-based salvage approach may facilitate implant preservation and improve final reconstruction rates. Early, case-specific conservative management, tailored to local microbiologic patterns, may optimize outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/4668584","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148834689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}